Due to a recent 2022 recommendation from the World Health Organization’s (WHO) Expert Advisory Group on Immunization, based on clinical trial data, health authorities in many countries are questioning this. switching from a 2-dose HPV vaccination approach to a single-dose regimen.
The team uses HPV-ADVISE, a dynamic individual transmission model of HPV infections and diseases to model the outcomes of different types of vaccination programs, here in 2 provinces, Quebec, a province with high HPV vaccination coverage rather high (around 85%), and Ontario, whose vaccination coverage is lower (around 65%).
One of the main authors, Dr. Marc Brisson, professor of mathematical modeling and health economics at the CHU de Québec–Université Laval, comments on this research: “the results have important implications in public health, not only in Canada but also in other similar high-income countries ».
The study thus models different scenarios based on 1 and 2 dose approaches. The analysis concludes that:
- a 1-dose gender-neutral vaccination strategy
could prevent a similar number of cervical cancers as the current 2-dose approach;
- all 1-dose vaccination scenarios, even the most pessimistic, turned out to correspond to a more efficient use of HPV vaccines versus 2-dose vaccination;
- These scenarios all appear to be able to lead to the elimination of cervical cancer, here in Canada and by 2032 to 2040.
“More efficient” use of vaccine doseswith the single dose regimen, is explained in particular by the savings possibilities linked to this transition to 1 dose and the greater flexibility of this vaccination approach which could promote the vaccination coverageespecially in regions where coverage is not optimal.
With this in mind, at 1 dose, regular monitoring of vaccine protection would be recommended in order to detect, where applicable, signs of reduction in protection.
Related News :